Circulating tumor cells and emerging blood biomarkers in breast cancer

Current Opinion in Oncology

Volumn 22, Issue 6, 2010, Pages 552-558

  Criscitiello, Carmen ^a   Sotiriou, Christos ^a   Ignatiadis, Michail ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

blood biomarkers; breast cancer; circulating tumor cells; prediction; prognosis

Indexed keywords

BEVACIZUMAB; CA 15-3 ANTIGEN; CANCER ANTIGEN 27-29; CD44V ANTIGEN; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; FOCAL ADHESION KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MICRORNA; MUCIN 1; NUCLEIC ACID; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C;

BLOOD SAMPLING; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; EPITHELIUM CELL; FLOW CYTOMETRY; GENE REARRANGEMENT; HETEROZYGOSITY LOSS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE MICROSCOPY; MEDLINE; METASTASIS; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVIEW; TUMOR CELL;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASTIC CELLS, CIRCULATING; TUMOR MARKERS, BIOLOGICAL;

EID: 77958486873     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833de186     Document Type: Review

References (49)

1. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8:329-340.
2. Ignatiadis M, Georgoulias V, Mavroudis D. Micrometastatic disease in breast cancer: clinical implications. Eur J Cancer 2008; 44:2726-2736.
3. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10:6897-6904.
4. Pachmann K, Clement JH, Schneider CP, et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005; 43:617-627.
5. Alix-Panabieres C, Vendrell JP, Pelle O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007; 53:537-539.
6. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450:1235-1239.
7. Talasaz AH, Powell AA, Huber DE, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009; 106:3970-3975.
8. Stathopoulou A, Ntoulia M, Perraki M, et al. A highly specific real-time RT-PCR method for the quantitative determination of CK-1 9 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int J Cancer 2006; 119:1654-1659.
9. Benoy IH, Elst H, Philips M, et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006; 94:672-680.
10. Zieglschmid V, Hollmann C, Bocher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 2005; 42:155-196.
11. Ignatiadis M, Xenidis N, Perraki M, et al. Different prognostic value of cytokeratin-1 9 mRNA-positive circulating tumor cells according to estrogen receptor and HER2 status in early breast cancer. J Clin Oncol 2007; 25:5194-5202.
12. Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008; 26:1208-1215.
13. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008; 14:7004-7010.
14. Coumans FA, Doggen CJ, Attard G, et al. All circulating EpCAM+CK+. Ann Oncol 2010 [E-pub ahead of print]
15. Tibbe AG, Miller MC, Terstappen LW. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007; 71:154-162.
16. Martin M, Garcia-Saenz JA, Maestro De lasCasas ML, et al. Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis. Anticancer Res 2009; 29:4185-4187.
17. Sandri MT, Zorzino L, Cassatella MC, et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol 2010; 17:1539-1545.
18. Sieuwerts AM, Kraan J, Bolt J, et al. Antiepithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009; 101:61-66.
19. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351:781-791.
20. Botteri E, Sandri MT, Bagnardi V, et al. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat 2010; 122:211-217.
21. Maestro LM, Sastre J, Rafael SB, et al. Circulating tumor cells in solid tumor in metastatic and localized stages. Anticancer Res 2009; 29:4839-4843.
22. Mego M, De Giorgi U, Hsu L, et al. Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol 2009; 20:1824-1828.
23. Bidard FC, Mathiot C, Degeorges A, et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 2010. [E-pub ahead of print]
24. Giordano A, Giuliano M, Hsu L, et al. Prognostic value of circulating tumor cells (CTC) in metastatic breast cancer (MBC): correlation with immunohis-tochemically defined molecular subtypes and metastatic disease sites. J Clin Oncol 2010; 28:7s [suppl; abstr 1000].
25. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluor-odeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 2009; 27:3303-3311.
26. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 2010; 21:33-39.
27. Liu MC, Shields PG, Warren RD, et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009; 27:5153-5159.
28. NakamuraS, Yagata H, OhnoS, et al. Multicenterstudy evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010; 17:199-204.
29. Bardia A, Huang P, Zhang Z, et al. Circulating tumor cell (CTC) and CA2729 as predictors of outcome in patients with metastatic breast cancer (MBC) in the prospective TBCRC 005 biomarker study. J Clin Oncol 2010; 28:7s [suppl; abstr 1001].
30. Tewes M, Aktas B, Welt A, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009; 115:581-590.
31. Camara O, Jorke C, Hammer U, et al. Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment. J Cancer Res Clin Oncol 2009; 135:643-647.
32. Pestrin M, Bessi S, Galardi F, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009; 118:523-530.
33. Payne RE, Yague E, Slade MJ, et al. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics 2009; 10:51-57.
34. Theodoropoulos PA, Polioudaki H, Agelaki S, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010; 288:99-106.
35. Bidard FC, Mathiot C, DelalogeS, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 21:729-733.
36. Riethdorf S, Muller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010; 16:2634-2645.
37. Biggers B, Knox S, Grant M, et al. Circulating tumor cells in patients undergoing surgery for primary breast cancer: preliminary results of a pilot study. Ann Surg Oncol 2009; 16:969-971.
38. Lang JE, Mosalpuria K, Cristofanilli M, et al. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 2009; 113:501-507.
39. Xenidis N, Ignatiadis M, Apostolaki S, et al. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009; 27:2177-2184.
40. Alix-Panabieres C, Vendrell JP, Slijper M, et al. Full-length cytokeratin-1 9 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 2009; 11:R39.
41. Rack B, Schindlbeck C, Andergassen U, et al. Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: the SUCCESS trial. J Clin Oncol 2010; 28:7s [suppl; abstr 1003].
42. Fehm T, Hoffmann O, Aktas B, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009; 11:R59.
43. Calleri A, Bono A, Bagnardi V, et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 2009; 15:7652-7657.
44. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007; 25:5287-5312. (Pubitemid 350232263)
45. Beck J, Urnovitz HB, Mitchell WM, Schutz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010; 8:335-342.
46. Schwarzenbach H, Pantel K, Kemper B, et al. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res 2009; 11:R71.
47. Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010; 251:499-505.
48. Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010; 2:20ra14.
49. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139:131 5-1326.